Evolus Expands Estyme® Rights to Canada, Australia, NZ, Eyes 2028 Launch
EOLS sits 57% above its 52-week low of $3.86.
Summary
Evolus has expanded its partnership with Symatese to exclusively commercialize the Estyme® injectable HA gel collection in Canada, Australia, and New Zealand, with expected launches in 2028 pending regulatory approvals. This completes the company's goal of offering a consistent neurotoxin-plus-filler portfolio across all its international markets, where the combined addressable market is approximately $500 million annually. The deal involves an upfront payment, regulatory milestone payments, and a mid-single digit royalty on net sales, and is expected to be accretive to international gross margins. This follows the recent exclusive U.S. licensing deal for Profhilo® and the termination of the ATM program, reinforcing Evolus's strategy to build a multi-product aesthetic platform. The expansion leverages existing commercial infrastructure and could strengthen the company's competitive position in the growing medical aesthetics market.
At the time of this announcement, EOLS was trading at $6.05 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $398.4M. The 52-week trading range was $3.86 to $9.35. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: BusinessWire.